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Abstract
This study sought to improve an existing live attenuated influenza vaccine (LAIV) by including 
nucleoprotein (NP) from wild-type virus rather than master donor virus (MDV). H7N9 LAIV 
reassortants with 6:2 (NP from MDV) and 5:3 (NP from wild-type virus) genome compositions 
were compared with regard to their growth characteristics, induction of humoral and cellular 
immune responses in mice, and ability to protect mice against homologous and heterologous 
challenge viruses. Although, in general, the 6:2 reassortant induced greater cell-mediated 
immunity in C57BL6 mice than the 5:3 vaccine, mice immunized with the 5:3 LAIV were better 
protected against heterologous challenge. The 5:3 LAIV-induced CTLs also had better in vivo 
killing activity against target cells loaded with the NP366 epitope of recent influenza viruses. 
Modification of the genome of reassortant vaccine viruses by incorporating the NP gene from 
wild-type viruses represents a simple strategy to improve the immunogenicity and cross-protection 
of influenza vaccines.
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1. Introduction
Influenza A viruses are highly contagious respiratory pathogens that continuously threaten 
human populations. Almost every year, there are epidemics of 3–5 million cases of severe 
influenza worldwide, of which at least 250,000 are fatal (Fifth meeting of National Influenza 
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Centers, 2012). The most effective tool for controlling influenza is vaccination. There are 
two main kinds of influenza vaccine currently in wide use: inactivated influenza vaccine 
(IIV) and live attenuated influenza vaccine (LAIV).
Immunization with IIV induces mainly humoral immune responses to the viral surface 
glycoproteins, hemagglutinin (HA) and neuraminidase (NA). However, this immunity is 
strain-specific and gives little protection against drifted variants of the virus. In contrast, 
immunization with LAIV induces a wide spectrum of immune responses, including local 
(mucosal) and T-cell-mediated immunity, in particular CD8+ cytotoxic T-cells (CTLs) 
(Tamura et al., 2005). CTL-driven immunity is cross-reactive and recognizes conserved 
epitopes within viral proteins, affording protection against different subtypes of influenza A 
virus (Kreijtz et al., 2008). One of the major targets for the CTL immune response is a 
molecule of viral nucleoprotein (NP), which contains multiple immunodominant CTL 
epitopes (Grant et al., 2013; Thomas et al., 2006).
LAIV strains are routinely prepared by either classical reassortment or reverse genetics, and 
usually comprise HA and NA genes derived from wild-type influenza virus (seasonal or 
potentially pandemic). The remaining six genes, including the NP gene, are derived from an 
attenuated master donor virus (MDV) (the so-called 6:2 genome composition) 
(Aleksandrova, 1977; Jin and Subbarao, 2015). The most widely used donor viruses – A/
Leningrad/134/17/57 (Len/17) in Russia and A/Ann Arbor/6/60 (A/AA) in the USA and 
Europe – were isolated nearly 60 years ago. It is possible that the nucleoprotein of influenza 
viruses could have significantly evolved during this period, despite its relatively conserved 
nature, resulting in a significant change in its antigenic properties. Thus the NP-specific 
CTL immunity induced by vaccination with classical LAIVs may not be effective against 
currently circulating influenza viruses. The most straightforward way to overcome this 
problem would be to include the wild-type NP gene in the genome of the LAIV reassortant 
virus, i.e. to switch from a 6:2 to a 5:3 genome composition (Isakova-Sivak et al., 2016). 
Such a modification of the vaccine virus genome would require a thorough understanding of 
the properties of the new LAIV reassortants, including in vitro and in vivo characterization, 
as well as their evaluation in clinical trials.
This paper reports a comparison of H7N9 LAIV reassortants with 6:2 and 5:3 genome 
compositions, with regards to their growth characteristics, induction of humoral and cellular 
immune responses in C57BL/6 (H2b) mice, and ability to protect animals against challenge 
with homologous and heterologous viruses. This particular subtype was selected because of 
its ability to induce humoral and cell-mediated immunity in C57BL/6 mice, and also 
because the NP of Len/17 and H7N9 virus have significant differences in the murine 
immunodominant epitope NP366–374, and thus are a good model for comparative epitope-
specific cell-mediated immunogenicity studies (Thomas et al., 2006).
2. Materials and methods
2.1. Materials
H7N9 LAIV reassortant virus with a 6:2 genome composition (H7N9 LAIV 6:2) was 
prepared by classical reassortment in eggs and was tested in preclinical and clinical trials (de 
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Jonge et al., 2016; Rudenko et al., 2016). This virus possesses the HA and NA genes of 
wild-type (wt) A/Anhui/1/2013 (H7N9) strain; the remaining genes come from A/
Leningrad/134/17/57 (H2N2) MDV. The corresponding H7N9 LAIV 5:3 reassortant virus 
with the NP gene inherited from the H7N9 virus rather than the MDV was generated by 
means of reverse genetics. Both viruses were fully sequenced and found to be identical apart 
from the NP gene.
Master donor virus A/Leningrad/134/17/47 (Len/17) and its wild-type precursor A/
Leningrad/134/57 (H2N2) (Len134 wt) were obtained from the repository of the Institute of 
Experimental Medicine (Saint Petersburg, Russia). Low-pathogenic avian influenza virus A/
mallard/Netherlands/12/2000 (H7N3) was obtained from the repository of the Centers for 
Disease Control and Protection (CDC) (Atlanta, GA, USA). In addition, two engineered 
viruses were generated for challenge experiments: an H7N9-PR8 5:3 reassortant, possessing 
the HA, NA and NP genes of wt H7N9 virus and five genes from A/Puerto Rico/8/34 
(H1N1) (PR8) virus; and an H1N1 7:1 virus, containing the NP gene from wt H7N9 virus 
and seven genes from the PR8 virus. All viruses were propagated in 10–11-D-old chicken 
embryos for two days at 33 °C and stored in aliquots at −70 °C.
C57BL6 mice of 8–10 weeks old were purchased from the laboratory breeding nursery of 
the Russian Academy of Sciences “Stolbovaya” (Moscow region, Russia).
NP366–374 peptides (ASNENMDTM and ASNENMEAM) were chemically synthesized by 
Almabion Ltd (Russian Federation), with a purity of over 95%, as shown by high-
performance liquid chromatography (HPLC). Peptides were reconstituted in dimethyl 
sulfoxide (DMSO) to a concentration of 1 mM and stored at −70 °C in aliquots.
2.2. Methods
2.2.1. CTL epitopes in circulating influenza A viruses—In order to predict the 
effectiveness of LAIV CTL immunity, we assessed the conservation of selected CTL 
epitopes in 757 unique NP sequences of influenza A viruses of H1N1 and H3N2 subtypes 
circulating in 2009–14, using the Immune Epitope DataBase (IEDB). Influenza A virus 
sequences were obtained from the Influenza Virus Sequence Database of the National 
Center for Biotechnology Information (NCBI) (Bao et al., 2008). CTL epitopes in the MDV 
NP sequence were screened with netCTL major histocompatibility complex I (MHCI) 
peptide binding and netChop proteasome processing prediction algorithms (Larsen et al., 
2007). The immunogenicity of CTL epitopes was estimated using the T cell class I peptide 
MHC (pMHC) immunogenicity predictor algorithm (Calis et al., 2013); peptides with an 
immunogenicity score above 0 were assumed to be immunogenic. Conservation of 
immunogenic CTL epitopes was estimated by conservancy analysis, with sequence identity 
threshold equal to 100% (Bui et al., 2007). For murine experiments, CTL epitope–MHC 
binding affinity was predicted using the netMHCpan algorithm (Hoof et al., 2009).
2.2.2. Growth characteristics of H7N9 LAIV 6:2 and 5:3 reassortants in vitro—
Temperature-sensitive (ts) and cold-adapted (ca) phenotypes of the studied viruses were 
determined by titration at different temperatures in eggs: 38 °C compared with 33 °C for the 
ts phenotype, and 26 °C compared with 33 °C for the ca phenotype. The Len/17 and Len134 
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wt viruses were used as control viruses possessing the opposite ts/ca phenotypes. Eggs were 
inoculated with 10-fold virus dilutions and incubated for either 48 h (at 33 °C or 38 °C) or 6 
days (at 26 °C). The growth characteristics of the H7N9 LAIV viruses were analysed in 
Madin Darby canine kidney (MDCK) cells: cell monolayers were infected with the viruses 
at a multiplicity of infection (MOI) of 0.01 and 0.001 in triplicate; 150 µl of the media were 
collected every 12 h and stored at −70 °C prior to titration by 50% tissue culture infective 
dose (TCID50). Virus titers in eggs and MDCK cells were calculated by the Reed and 
Muench method and expressed in terms of log10 50% egg infective dose (EID50)/ml and 
log10TCID50/ml, respectively.
2.2.3. Growth characteristics of H7N9 LAIV 6:2 and 5:3 reassortants in vivo—
Groups of eight female C57BL6 mice were anesthetized with ether and given 50 µl of virus 
suspension containing 106 EID50 by the intranasal (IN) route. The Len/17 and Len134 wt 
viruses were used as control viruses: the former is characterized by an attenuated (att) 
phenotype, while the latter has a non-att phenotype. Nasal turbinates and lungs were 
collected on days 3 and 6 after inoculation and stored frozen at −70 °C until used for 
homogenization. Tissue homogenates were prepared in 1 ml of sterile phosphate-buffered 
saline (PBS) containing antibiotic and antimycotic (Invitrogen, UK), using a small bead mill 
TissueLyser LT (QIAGEN, Germany). The clarified supernatants were used to determine 
virus titers by limiting dilutions in eggs, as described above. The limit of detection was 1.2 
log10/ml.
2.2.4. Immunogenicity and protection studies—Groups of 54 female C57BL6 mice 
were given two doses of 50 µl of either H7N9 LAIV 6:2 or H7N9 LAIV 5:3 virus 
suspension containing 106 EID50 intranasally, 21 days apart. Control animals received the 
same volume of PBS. Blood and bronchoalveolar lavage (BAL) samples were collected from 
six mice in each group on day 21 after each dose, to assess antibody immune responses. Six 
mice from each group were euthanized on day 7 after each dose and spleen samples were 
harvested for the assessment of cell-mediated immune responses. In vivo killing activity of 
CTLs was studied in six mice of each study group on day 7 after the second dose. The 
remaining 24 animals were used for the assessment of protective efficacy of the H7N9 
LAIVs.
2.2.5. Antibody responses—Serum antibody titers were determined by 
hemagglutination-inhibition assay (HAI), and IgG by enzyme-linked immunosorbent assay 
(ELISA), as described previously (Isakova-Sivak et al., 2014) with some modifications. IgA 
antibodies were determined in BAL specimens collected on days 21 and 42 using 1 ml of 
sterile PBS.
For HAI, serum samples were treated with chicken red blood cells to remove nonspecific 
inhibitors and quantified against four HA units of the following viruses: (i) H7N9 LAIV 6:2; 
(ii) H7N9 LAIV 5:3; (iii) H7N3 wt; and (iv) H1N1 7:1. ELISA was performed with the 
same four antigens. (The wild-type H7N9 virus could not be used as antigen in these tests, 
because of the lack of a biosafety level 3 facility).
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Briefly, 96-well microtitration plates (Microlon, Greiner bio-one, Germany) were coated 
with 100 µl of sucrose-purified virus antigen containing 16 HA units in PBS overnight at 
4 °C. The plates were washed with 0.1% Tween 20 in PBS (PBST), then blocked with 200 µl 
of 1% bovine serum albumin (BSA) in PBS for 2 h. Twofold dilutions of sera were prepared 
starting from 1:2 (for IgA antibody) and 1:10 (for IgG antibody) and added to the coated 
wells. The plates were incubated overnight at 4 °C, then washed six times with PBST. 
Bound antibodies were detected with 50 µl of horseradish peroxidase-conjugated goat anti-
mouse IgA or IgG (Sigma-Aldrich). Antibody titer was defined as the last dilution with an 
optical density (OD) at least double the mean OD in the control wells (containing all 
components except the serum specimens).
2.2.6. Virus/epitope-specific murine CTLs—Cytotoxic CD8+ T cells were analysed 
by intracellular cytokine staining (ICS) to gamma-interferon. In brief, murine splenocytes 
were isolated and red blood cells were lysed by ammonium-chloridepotassium lysing buffer. 
In some experiments, cells were cryoconserved in heat-inactivated fetal bovine serum (FBS) 
with 10% DMSO. For in vitro virus stimulation, 106 cells were incubated with sucrose-
gradient purified viruses at an MOI of 1.0 EID50 per cell for one hour in 100 µl of complete 
RPMI-1640 without FBS in microtitration U-bottom well plates. Next, 50 µl of medium with 
FBS was added, to a final FBS concentration of 10%. Peptide stimulation experiments used 
the same procedures without addition of virus. After 16–18 h, GolgiPlug solution (Becton 
Dickinson, USA) – alone or with peptide (for peptide stimulation experiments) – or control 
solution was added and the mixture incubated for a further five hours. ICS was performed 
with Cytofix/Cytoperm kit (Becton Dickinson, USA) according to the manufacturer's 
instructions. Samples were stained with live/dead fixable stain (Invitrogen, USA), anti-CD3, 
anti-CD8 and anti-gamma-interferon antibody-conjugates (Becton Dickinson, USA). 
Samples were fixed in 1% paraformaldehyde and stored in a dark cool place prior to flow 
cytometric analysis. At least 300 000 events were measured using a Navios flow cytometer 
(Beckman Coulter, USA). The percentage of virus/peptide-specific CTLs was calculated by 
subtracting the gammainterferon-positive CD8+ T cells from the negative control (virus/
peptide diluents probes).
2.2.7. Cytotoxic activity of CTLs in vivo—This was performed by CTL in vivo assay 
as described by Durward et al. Durward et al. (2010), with some modifications. Briefly, 
splenocytes from naïve C57BL6 mice were harvested and red blood cells lysed. Cells were 
divided into three parts (of 2×108 cells each) in 10 ml of complete RPMI-1640, and loaded 
with 1 µm peptide or an equal volume of peptide diluent (control) for one hour. Each sample 
was then washed and stained with either 40, 20 or 10 mM carboxyfluorescein diacetate 
succinimidyl ester (CFSE). The target cells were washed, filtered, and mixed with equal 
amounts of cells stained with each CFSE concentration. Two million target cells were 
administered in 100 µl of Hanks solution to anesthetized mice by retro-orbital injection. The 
following day, the mice were sacrificed and splenocytes were harvested and processed by 
flow cytometry. Cytotoxicity was represented as the ratio of the count of peptide-loaded 
target cells to that of control target cells.
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2.2.8. Assessment of protective efficacy—To assess protection, 24 mice from each 
study group were divided into three sub-groups and infected intranasally with 50 µl of one of 
the following three challenge viruses at a dose of 106 EID50: (i) H7N9-PR8 5:3; (ii) H7N3 
wt; or (iii) H1N1 7:1. The first of these was a recombinant virus on a PR8 backbone with 
HA, NP and NA genes derived from H7N9 virus. This virus was considered as homologous 
challenge, since wild-type H7N9 virus could not be used. The third challenge virus was a 
recombinant virus based on PR8, in which the NP gene was replaced by that of the H7N9 
strain (i.e. a 7:1 reassortant). Four mice in each challenge group were euthanized on days 3 
and 6 after infection, and lungs and nasal turbinates were harvested for virus titration. Virus 
titers in tissue homogenates were determined by titration on MDCK cells by TCID50 assay.
2.2.9. Statistical analyses—Data were analysed with the Statistica software (version 
6.0; Statsoft Inc.). The statistical significance of the difference between viral titers in organs 
of mice was determined by the Mann-Whitney U-test. Differences in CTL levels and log2-
transformed HAI and ELISA antibody titers were also subjected to the Mann-Whitney U-
test. P values of < 0.05 were considered significant.
2.2.10. Ethics statement—The handling of animals and chicken embryos was performed 
in accordance with the “Manual for laboratory animals and alternative models in biomedical 
research” (Manual for laboratory animals and alternative models in biomedical research 
Russian, 2010). Fertilized eggs used for virus propagation were discarded in an appropriate 
manner, according to Russian sanitary-epidemiological rules SP 1.3.2322-08 (approved 28 
January 2008). Mouse experiments were reviewed and approved by the Institutional Local 
Ethical Committee.
3. Results
3.1. CTL epitopes in circulating influenza A viruses
Using the netCTL algorithm, we selected 138 unique 9-mer peptides from the LAIV NP 
with high binding affinity to the MHC of 11 human leukocyte antigen (HLA) supertypes 
(A1, A2, A3, A24, A26, B8, B27, B39, B44, B58, B62). Eighteen of them were found to be 
highly immunogenic by the T cell class I pMHC immunogenicity predictor algorithm with 
default mask (1, 2 and C-terminus amino acid) (Table 1). Only 8 of the 18 epitopes were 
highly conserved in recent strains of influenza A virus (conservancy in 90% or more of 
assessed sequences), suggesting that the nucleoprotein has evolved significantly during the 
past 60 years.
3.2. Growth characteristics of H7N9 LAIV 6:2 and 5:3 reassortants in vitro
Comparative studies of the growth characteristics of 6:2 and 5:3 H7N9 LAIV reassortants 
demonstrated that the NP gene had no impact on the ts/ca phenotypes: both the 6:2 and the 
5:3 reassortants replicated poorly in eggs at 38 °C, but grew well at 26 °C (Fig. 1). These 
LAIVs recapitulated the ts/ca phenotypes of Len/17 MDV, in contrast to the wild-type virus 
Len134, which replicated well at 38 °C, but its growth at 26 °C was inefficient (Fig. 1). 
Although the titers of the 5:3 reassortant were slightly lower than those of the 6:2 
counterpart in eggs at 33 °C and 26 °C (difference 0.5–0.7 log10EID50), the kinetics of virus 
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growth in MDCK cells at an MOI of 0.01 were identical (Fig. 2A). Only at the lower MOI of 
0.001 was a slightly slower accumulation of the 5:3 virus seen in cell culture; however, the 
final titer of the 5:3 reassortant was higher than that of 6:2 virus (Fig. 2B).
3.3. Growth characteristics of H7N9 LAIV 6:2 and 5:3 reassortants in vivo
The two H7N9 LAIV viruses showed similar growth patterns in mouse respiratory organs: 
the viruses grew efficiently in the upper respiratory tract (URT), achieving titers of 4.0–4.4 
log10EID50/ml on day 3. The replication was prolonged and on day 6 the viruses were 
detected in the URT at titers of 3.0–3.1 log10EID50/ml. In contrast, the growth of the viruses 
in the lower respiratory tract was significantly impaired and titers did not exceed 1.4 
log10EID50/ml, similar to the Len/17 MDV (Fig. 3). Interestingly, the magnitude of 
replication of both H7N9 LAIVs in URT was significantly higher than that of Len/17 MDV, 
suggesting the positive impact of H7N9 surface proteins on LAIV infectivity. These data 
show the classical replication pattern of attenuated influenza viruses in a mouse model, and 
this is in contrast to Len134 WT virus, which could grow in lung tissues up to 5.4 
log10EID50/ml and this replication was prolonged (Fig. 3).
Overall, the NP gene of wild-type H7N9 influenza virus had little or no impact on virus 
growth in vitro or in vivo.
3.4. Antibody responses after immunization with H7N9 LAIV 6:2 and 5:3 reassortants
The two LAIV viruses induced identical HAI antibody titers to all antigens tested, after one 
and two doses (Fig. 4). These data are not unexpected, since the vaccines share the same HA 
molecule. In contrast, serum IgG and BAL IgA antibody titers detected by ELISA differed 
significantly, depending on the antigen used. Thus, when H7N9 LAIV 6:2 virus was used as 
antigen, significantly higher IgG and IgA antibody titers were seen in mice immunized with 
H7N9 LAIV 6:2 reassortant than those in the H7N9 LAIV 5:3 vaccine group (Fig. 4A). 
However, when the H7N9 LAIV 5:3 virus was used as antigen, no differences were seen in 
serum IgG and BAL IgA antibody titers in the two vaccine groups (Fig. 4B). Since the two 
antigens differ only in the source of NP, these data reflect the impact of anti-NP antibody in 
overall virus immunogenicity. It is noteworthy that slightly higher serum IgG antibody titers 
were detected in mice immunized with two doses of 5:3 vaccine virus, when heterologous 
H7N3 virus was used as antigen (p=0.049), suggesting that the 5:3 virus induces IgG 
antibody that is more cross-reactive with recent H7 viruses (Fig. 4C). Some cross-reactive 
serum IgG and BAL IgA antibodies to heterologous H1N1 7:1 virus were observed after two 
doses of either H7N9 LAIV; there was no significant difference between the vaccine groups 
(Fig. 4D). Overall, the two H7N9 LAIVs induced similar antibody responses in mice.
3.5. Virus-specific CTL responses after immunization with H7N9 LAIV 6:2 and 5:3 
reassortants
The main aim of this study was to compare NP-specific cell-mediated immunity to LAIV 
viruses that differ only in the source of their NP. Administration of either 6:2 or 5:3 LAIV 
induced CTL immunity in C57BL6 mice after each dose (Fig. 5A). A second dose of either 
LAIV boosted the levels of virus-specific CTLs; more dramatic induction of virus-specific 
CTLs was noted in mice immunized with the 6:2 virus. Interestingly, despite the higher CTL 
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responses in the 6:2 LAIV group, these T-cells were mainly targeted to virus containing old 
NP (i.e. 6:2 reassortant), while the CTL levels targeted to 5:3 LAIV were significantly lower 
(p=0.031). In contrast, the 5:3 LAIV induced lower levels of CTLs, but which responded 
equally to stimulation with 6:2 or 5:3 reassortant viruses (Fig. 5).
3.6. NP366–374 epitope-specific CTL responses after immunization with H7N9 LAIV 6:2 and 
5:3 reassortants
Fig. 5B shows the NP366–374-specific CTL immune response in mice after administration of 
H7N9 6:2 or 5:3 LAIV. CTLs were induced by both vaccine viruses and were boosted by a 
second vaccine dose. As with whole-virus stimulation, 6:2 LAIV induced higher levels of 
epitope-specific CTLs than 5:3 LAIV. While both viruses induced cross-reactive epitope-
specific CTLs, the proportion of CTL clones targeted to the NP epitope from H7N9 virus in 
relation to those targeted to the epitope from Len/17 was significantly (more than 30- fold) 
higher in the 5:3 LAIV group. These data suggest that the two mutations in the NP366 
epitope had an impact on the cross-reactivity of the epitope-specific CTLs.
3.7. In vivo cytotoxic activity of CTLs induced by 6:2 and 5:3 H7N9 LAIVs
Fig. 6 shows the results of the in vivo assay to estimate the ability of CTLs of LAIV-
immunized mice to kill NP366–374-loaded target cells. As expected, Len/17 NP366-loaded 
targets were more effectively killed in mice immunized with 6:2 LAIV than in those 
immunized with 5:3 LAIV. The proportion of peptide-loaded to control cells in mock-
immunized mice was 1.2 compared with 0.8 in mice immunized with 6:2 LAIV-immunized, 
and 1.14 in 5:3 LAIV-immunized mice (Fig. 6A). In contrast, the proportion of H7N9 
NP366-loaded cells to control cells was significantly lower in 5:3 LAIV-immunized mice 
(1.4) than in mock-immunized mice (1.7), while the proportion of peptide-loaded cells in the 
6:2 LAIV group (1.5) was not significantly different than that for mock-immunized mice 
(Fig. 6B). This suggests that 5:3 LAIV-immunized mice should be better protected against 
influenza viruses carrying more recent NPs.
3.8. Protection against homologous and heterologous influenza viruses
Induced immunity in both LAIV groups was sufficient to fully protect mice from challenge 
with H7N9 virus: no infectious virus was detected in the lungs of immunized animals, while 
high pulmonary titers were observed in the control group (Fig. 7A).
After challenge with the second virus, a natural avian influenza isolate, lung titers in the 5:3 
LAIV-immunized group on day 3 were significantly lower than those in the control group 
(p=0.024); titers in the 6:2 LAIV-immunized animals were lower than in the control group, 
but the difference was not significant (p=0.077) (Fig. 7B). Although the difference between 
the study groups was not significant (p=0.19), these data suggest that the 5:3 reassortant 
gives better cross-protection than the 6:2 counterpart. Importantly, both vaccines resulted in 
faster clearance of the challenge virus: no virus was detected six days after challenge.
The third challenge virus, an H1N1 7:1 reassortant, in contrast to the PR8 virus, was not 
lethal for mice (data not shown). However, it replicated efficiently in the mouse lower 
respiratory tract. Strikingly, the protection profile in this challenge group was similar to that 
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for H7N3: though the difference between the LAIV groups was not statistically significant 
(p=0.29), mice immunized with 5:3 LAIV shed the virus at significantly lower levels than 
mock-immunized mice three days after challenge (p=0.024), while virus titers in 6:2 LAIV-
immunized mice were not significantly different from controls (p=0.11) (Fig. 7C). Overall, 
the immune responses induced by 5:3 H7N9 LAIV reassortant were more cross-protective 
than those induced by classical 6:2 LAIV.
4. Discussion
Live attenuated influenza vaccine has historically been generated by reassortment of genes 
from currently circulating or potentially pandemic wild-type influenza A virus with genes 
from an MDV. The current 6:2 genome structure was initially proposed because it was 
postulated that the HA and NA glycoproteins were the main targets for adaptive immune 
responses and should come from the wild-type parental virus, while the remaining genes 
determine the biological properties of the LAIV vaccine strain (high yield, ts/ca and 
attenuated phenotype) and should be derived from the MDV. However, more recently, 
studies of influenza-related immune responses have revealed that internal and non-structural 
proteins of influenza virus have an important impact on cell-mediated immune responses. 
Apparently, this type of immunity constrains the number of infected cells and reduces virus 
yield, but does not prevent the dissemination of free virions (Janeway et al., 2001; Bender et 
al., 1992; Moskophidis and Kioussis, 1998). CTL immunity is targeted to a number of 
influenza proteins, predominantly epitopes of internal proteins, such as matrix protein and 
nucleoprotein (Grant et al., 2013; Moskophidis and Kioussis, 1998; Chen et al., 2014). 
Those proteins are relatively conserved as a result of sequence functional constraints and 
CTL immunity against them is cross-reactive between influenza subtypes (Saha et al., 2006; 
Rimmelzwaan et al., 2009).
Recently Machkovech et al. (2015) have shown evidence of selective pressure on 
nucleoprotein CTL epitopes in human influenza A virus. Another study demonstrated the 
possibility of generating CTL immune- escaped influenza virus variants within an immune-
compromised patient persistently infected with an influenza virus (Valkenburg et al., 2013). 
Moreover, there is a risk that CTL immunity after human viruses exposure will be 
ineffective against zoonotic influenza viruses with diversified CTL epitope sequences, such 
as H7N9 avian-origin virus (De Groot et al., 2013).
Russian LAIVs contain NP from an H2N2 human viral strain that originated in 1957. We 
found that only 44% of the CTL epitopes of the Len/17 MDV nucleoprotein are conserved in 
currently circulating influenza A H1N1 and H3N2 viruses. The Len/17 NP-specific CTLs 
induced after immunization with classical LAIV might therefore be relatively inefficient in 
protecting against recent viruses. Modification of the genome composition of LAIV strains 
to include the NP of the wild-type strain may overcome this problem.
Since humanized mice were not available for our studies, we searched for a good virus 
subtype to study NP-specific CTL response in C57BL6 mice, a mouse model for which the 
T-cell immune response to influenza infection has been well characterized (Thomas et al., 
2006). The H7N9 subtype was considered a good model virus because H7N9 LAIV 
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replicated well in the C57BL6 mouse inducing strong antibody and cellular immune 
responses (our unpublished data, confirmed in this study), and also due to significant 
differences in the murine immunodominant epitope NP366–374. Earlier studies indicated that 
while the primary CTL response to PR8 virus was driven by the two viral determinants 
(PA224–233 and NP366–374), the NP366–374-specific CD8+ T cells dominated the secondary 
response to PR8 challenge, accounting for up to 80% of the influenza-specific CTLs 
(Thomas et al., 2006; Belz et al., 2000). In our study, we used a two-dose immunization 
schedule because it better reflects the situation with humans who are usually primed to some 
extent due to previous exposure to influenza infection or immunization, whereas mice are 
immunologically naïve and two vaccine doses are required to induce substantial levels of 
antibody and cell-mediated immunity.
Our studies found that the NP of H7N9 virus had only a slight impact on the growth 
characteristics of the LAIV reassortant strain, in eggs, cell culture, and mouse respiratory 
organs. The infectivity of the 5:3 reassortant allowed functional antibody and cell-mediated 
immunity to be established after vaccination. In general, the 6:2 LAIV reassortant induced 
more pronounced ELISA antibodies and cell-mediated immune responses than the 5:3 LAIV 
virus, when measured against 6:2 LAIV virus (containing Len/17 NP). However, this 
superior immunogenicity disappeared when antibodies and CTLs were measured against 
viruses containing recent NPs. It was interesting that ELISA could detect different levels of 
IgG antibody against 6:2 and 5:3 LAIV antigens within one serum sample. Since these 
viruses differ only in the source of NP, it can be speculated that ELISA can also detect a 
subset of anti-NP antibody. Although NP is not normally found on the virion surface and 
theoretically anti-NP antibody should not be detected using whole-virion antigens, the use of 
detergent in some steps of our ELISA protocol might contribute to the binding of the anti-
NP antibody to the NP protein of the coating virions. The limitation of our study is the lack 
of purified nucleoproteins to measure NP-specific antibodies directly. The experimental set-
up did not allow the protective role of anti-NP antibody against heterologous challenge 
viruses to be distinguished from that of NP-specific CTLs. It should be noted that the 
protective effect of anti-NP antibody in C57BL6 mice against lethal challenge could be seen 
only with high concentrations of this antibody in mouse sera (Lamere et al., 2011).
The main purpose of this study was to determine whether the incorporation of wt NP into 
the genome of LAIV virus would be advantageous in terms of inducing cross-reactive CTLs 
and protecting mice against antigenically divergent viruses. As mentioned above, we used 
C57BL6 mice in which the CTL response is mainly restricted by the NP366–374 epitope 
(Thomas et al., 2006; Belz et al., 2000; Belz et al., 2000, 2001; Kedzierska et al., 2005; 
Young et al., 1994). This fragment differs in the 7th and 8th positions in Len/17 and H7N9 
NPs. These are the substitutions in TCR facing residue 7 (from acidic Asp to acidic Glu) and 
in MHC I anchoring residue 8 (from hydroxyl Thr to aliphatic Ala). These differences might 
be not critical for peptide-MHC I complex formation, because both peptides preserve high 
predicted binding affinity to H-2Db molecules by NetMHCpan 2.8 algorithm (data not 
shown). Unfortunately, the epitope processing prediction algorithms are not well fitted for 
murine machinery to utilize in this experiment. Nevertheless, both of them could be 
immunogenic but able to induce the CTL clones with different TCR recognition moieties. 
Through in vitro measurement of CTL cross-reactivity to NP366–374 epitopes, we estimated 
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that these amino acid substitutions were critical to pMHC-complex recognition by T-cell 
receptors. Thus, despite the higher CTL response specific for NP366Len/17 epitope in the 
6:2 LAIV-immunized mice, the proportions of NP366H7N9-specific CTLs relative to 
NP366Len/17-specific CTLs were 30 times lower in this vaccine group than in the 5:3 LAIV 
group. These results demonstrate the excessive induction of CTLs targeted to old irrelevant 
epitopes by classical 6:2 LAIV, unnecessarily loading the immune system. Moreover, the 5:3 
LAIV-immunized mice had the greatest specific NP366-targeted killing activity and 
protection against challenge viruses containing recent NPs. These experiments demonstrated 
the clear advantages of LAIVs with up-to-date CTL epitopes in inducing a relevant T-cell 
immune response, rather than producing a large immunological reaction to irrelevant 
antigens. Although we did not assess the other major immunodominant epitopes outside of 
NP protein, previous studies indicate that in mice infected with viruses from which dominant 
CTL epitopes have been eliminated the expansion of T cells reactive against subdominant 
epitopes might occur (Webby et al., 2003). Of note, the second major immunodominant 
epitope PA224–233 differs by one amino acid between Len/17 MDV and the two viruses used 
in the challenge studies: PR8 and H7N3 (Cys-2-Ser), therefore the expansion of CD8+ T 
cells against other conserved subdominant epitopes, such as PB1703–711, NS2114–121, 
M1128–135 might have contributed to the observed enhanced cross-protection of the 5:3 
LAIV. The fact that both 6:2 and 5:3 LAIVs efficiently protected mice against heterologous 
H1N1 viral challenge is in line with other studies demonstrating the heterosubtypic 
protection of LAIVs based on different backbones (Jang and Seong, 2013). This cross-
protective potential of LAIVs is mostly driven by the CTLs targeted to conserved viral 
proteins, and in our studies we attempted to further improve this mode of protection afforded 
by LAIVs.
The NP gene of Len/17 MDV does not bear any ts loci associated with the ts/att phenotypes 
of the Russian LAIV; these phenotypes are controlled by specific mutations located in PB2 
(V478L) and PB1 (K265N; V591I) (Isakova-Sivak et al., 2011; Kuznetsova et al., 2015). 
Therefore the Len/17 NP gene can be easily replaced with that of wild-type virus without 
compromising the biological properties of the LAIV virus. In contrast, the US A/AA-based 
LAIV contains a mutation in the viral NP (D34G) that, together with other mutations in the 
viral PB2 (N265S) and PB1 (K391E; E581G; A661T) are responsible of the ts phenotype of 
the MDV (Jin, 2003). However the other studies found that the four ts loci in PB2 and PB1 
proteins are sufficient to impart ts/att phenotypes to the genome of wild-type virus, 
suggesting that NP protein of A/AA MDV also can be substituted with WT NP without 
affecting important viral characteristics (Zhou et al., 2012; Jin et al., 2004).
The results of our study may also have implications for the improvement of inactivated 
influenza vaccines. In recent years, numerous studies have demonstrated the establishment 
of functional influenza- virus-specific CD8+ and CD4+ T cells after both intranasal and 
intramuscular immunization with IIV (Wang et al., 2015; Keijzer et al., 2014; Ann et al., 
2014). It would therefore also be important to reconsider the genome composition of 
reassortant viruses for IIVs. These viruses are usually prepared using highly egg-adapted 
virus A/ PR/8/34 (H1N1), which dates back to the 1930s, and the CTL epitopes of recent 
viruses have also significantly evolved since then.
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As a conclusion, we strongly recommend incorporating wild-type NP into the genome of 
seasonal LAIV and IIV reassortant viruses to improve cell-mediated immune responses.
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Replication of H7N9 LAIV influenza viruses and the control wild-type and cold-adapted 
H2N2 viruses in eggs at different incubation temperatures. Viruses stocks propagated in eggs 
at the permissive temperature (33 °C) were titrated by end-point dilutions at the permissive 
or non-permissive temperatures (26 °C and 38 °C). The bars represent virus titers at 
indicated temperature ± standard deviations (SD) (T lines). P values are shown for the two 
H7N9 LAIVs being compared in this study (Mann-Whitney U test). Dotted line indicates the 
assay limit of detection (1.2 log10EID50/ml).
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Replication of H7N9 LAIV 6:2 and 5:3 reassortant viruses in MDCK cells. Cell monolayers 
were infected with studied viruses at a multiplicity of infection (MOI) of 0.01 and 0.001 in 
triplicates and incubated at the permissive temperature (33 °C). Culture supernatants were 
collected every 12 h and stored at −70 °C prior to titration by 50% tissue culture infective 
dose (TCID50). Statistically significant differences between studied viruses are indicated 
with an asterisk (p < 0.05, Mann-Whitney U test). Dotted line indicates the assay limit of 
detection (1.1 log10TCID50/ml).
Isakova-Sivak et al. Page 16














Replication of H7N9 LAIV influenza viruses and the control wild-type and cold-adapted 
H2N2 viruses in respiratory organs of C57BL6 mice. Groups of 8 mice were inoculated i.n. 
with 106 EID50 of each virus; four mice from each group were euthanized on either day 3 or 
day 6 p.i.. Mouse respiratory tissues were collected and homogenized, and viral titers were 
determined by end-point titration in eggs. The virus titers are expressed as the mean 
log10EID50/ml ± SD (T lines). The limit of virus detection was 1.2 log10EID50/ml, indicated 
by a dotted line. Asterisks indicate significant differences in titers of H7N9 LAIV viruses 
compared to Len/17 MDV (p < 0.05, Mann-Whitney U test).
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Antibody immune responses in mice immunized with H7N9 LAIV 6:2 and 5:3 reassortants. 
Groups of 12 mice were inoculated i.n. with two doses of 106 EID50 of each LAIV virus 21 
days apart or mock-vaccinated. Mice sera and bronchoalveolar lavage (BAL) were collected 
from 6 mice in each group 21 days after the first dose and 21 days after the second dose. HI 
and ELISA tests were performed using egg-grown whole viruses as antigens (left panel 
indicates the antigens used in HAI and ELISA tests). Bars represent geometric mean with 
95% confidence interval calculated from log2-transformed HI and ELISA titers. Statistical 
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significance of differences between the vaccine groups was estimated by the Mann-Whitney 
test. Dotted line indicates the assay limit of detection.
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A. CTL immune responses in mice immunized with H7N9 LAIV 6:2 and 5:3 reassortants. 
Groups of 12 mice were inoculated i.n. with two doses of 106 EID50 of each LAIV virus 21 
days apart or mock-vaccinated. Mice splenocytes were collected from 6 mice in each group 
7 days after the first dose and 7 days after the second dose. Levels of IFNγ-secreting CD8+ 
T-cells were determined after whole-virus stimulation (A) or after stimulation with NP366 
peptide (B). Bars represent geometric mean with 95% confidence interval. Statistical 
significance of differences was estimated by the Mann-Whitney U test. Significant 
Isakova-Sivak et al. Page 20













differences between immunized and control groups are marked by asterisks (p < 0.01). The 
exact p-value is shown for in-group differences.
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In vivo cytotoxic activity of CTLs induced by 6:2 and 5:3 H7N9 LAIVs. Groups of 6 mice 
were inoculated i.n. with two doses of 106 EID50 of each LAIV virus 21 days apart or mock-
vaccinated. Splenocytes from naive C57BL/6 mice were loaded with either Len/17 (A) or 
H7N9 (B) NP366–374 peptides and adoptively transferred by retro-orbital injection to 
vaccinated mice on day 7 after the second dose. The next day, specific cytotoxicity was 
measured and represented as the ratio of the count of peptide-loaded target cells to that of 
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control target cells. Bars represent medians and minimum to maximum intervals. Statistical 
significance of differences was estimated by Mann-Whitney U test.
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Infectious viral titers in immunized mice challenged with homologous and heterologous 
viruses. Groups of 24 mice were inoculated i.n. with two doses of 106 EID50 of each LAIV 
virus 21 days apart or mock-vaccinated. Three weeks after second vaccination 8 mice from 
each group were challenged with either H7N9-PR8 5:3 reassortant virus (A) or H7N3 
wt.virus (B) or H1N1 7:1 reassortant virus (C). Three and six days post challenge lungs 
were collected from 4 mice from each group, and viral titers in homogenized tissues were 
determined by 50% tissue culture infective dose (TCID50).. The virus titers are expressed as 
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the mean log10TCID50/ml ± SD (T lines). The limit of virus detection was 1.1 
log10TCID50ml, indicated by a dotted line. Tissues in which no virus was detected were 
given a value of 1.1 log10 to calculate the mean titer. P values are calculated by Mann-
Whitney U test.
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